A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

NCT03567642 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Osimertinib
DRUG: Platinum
DRUG: Etoposide

Sponsor

Memorial Sloan Kettering Cancer Center